On Wednesday, Penumbra got an upgrade for its IBD SmartSelect Composite Rating from 94 to 97.
The new score means the company is now outperforming 97% of all stocks in terms of the most important fundamental and technical stock-picking criteria. The market's biggest winners often have a 95 or higher grade in the early stages of a new price run, so that's a good item to have on your checklist when looking for the best stocks to buy and watch.
Penumbra is now out of buy range after clearing the 211.19 entry in a flat base.
Looking For Winning Stocks? How To Invest In Both Bull And Bear Markets
The stock has a 98 EPS Rating, which means its recent quarterly and annual earnings growth is outpacing 98% of all stocks.
Its Accumulation/Distribution Rating of B shows moderate buying by institutional investors over the last 13 weeks.
The company reported a 27% EPS gain for Q3. Sales growth came in at 11%, down from 14% in the previous quarter.
Penumbra earns the No. 2 rank among its peers in the Medical-Products industry group. Globus Medical is the No. 1-ranked stock within the group.
